Prolongation of biologic dosing intervals in patient with stable psoriasis; a feasibility study

Teun van Gelder

[P26-5-2] Prolongation of biologic dosing intervals in patient with stable psoriasis; a feasibility study

Teun van Gelder¹, Ji Sun van Bezooijen², Martijn van Doorn³, Marco Schreurs⁴, Birgit Koch⁵, Henk te Velthuis⁶, Errol Prens⁷ (1.Erasmus MC, 2.Erasmus MC, 3.Erasmus MC, 4.Erasmus MC, 5.Erasmus MC, 6.Sanquin, 7.Erasmus MC)

Keywords:biologics, adalimumab, etanercept, ustekinumab, dosing interval prolongation

Abstract password authentication.
Password to view abstracts and 'Participants' page is announced on the e-blast sent to early-bird/advanced registrants on September 13. It is also on the page 7 of IATDMCT 2017 PROGRAM BOOK.

Presentation information

[P26-5] P26-5: Immunosuppressive drugs (4): Individualized dosage adjustment

[P26-5-2] Prolongation of biologic dosing intervals in patient with stable psoriasis; a feasibility study

Password